Fesoterodine is a drug approved in Europe and USA to treat an overactive bladder condition known in adults but due to lack of research it is not yet FDA approved for children. This bladder condition has been associated with damage to the nervous system and is known as Neurogenic detrusor over activity (NDO).
The purpose of this trial is to study the effects of the Fesoterodine medicine provided to children diagnosed with NDO. We will also compare the effects of Fesoterodine with Oxybutynin, a widely approved medicine commonly used to treat NDO in children.
For more information visit: https://clinicaltrials.gov/ct2/show/NCT01557244?term=Fesoterodine&rank=1
Children between 6-17 years of age diagnosed with neurogenic detrusor overactivity (NDO).
Pfizer, Inc.
Director, Pediatric Urology; Pediatric Urologist
Pediatric UrologyKidney Stone Clinic
While we are ranked among the best children's hospitals in the country, it's our compassionate approach to treatment that makes us truly exceptional. Through a combination of revolutionary treatments and extraordinary patient experiences, our care does more than heal. It brings the entire family together for emotional support and understanding across multiple locations to reach you in the community where you live. Learn more...
By using this site, you consent to our use of cookies. To learn more, read our privacy policy.
